Developer docs
API playgroundTry for free, no card

Search company profiles

4E Therapeutics

Full company profile

uuid0002wca

Namestring
4E Therapeutics
Legal namestring
4E Therapeutics Inc
Company typeenum
Private
Founded yearint
2019
Descriptiontext

4E Therapeutics is a neuroscience drug development company founded in 2019 in Austin, Texas, focused on non-opioid treatments for chronic neuropathic pain and related pain disorders. The company's scientific premise is that MNK-mediated phosphorylation of eIF4E is the final common pathway linking injury to nociceptor plasticity that drives chronic pain, and that inhibiting this pathway in peripheral sensory neurons can suppress pain signal generation without the central nervous system side effects and addiction risk associated with opioid analgesics. Its core technology is a proprietary library of more than 150 small molecule MNK inhibitors, optimized through medicinal chemistry to be peripherally-restricted and orally bioavailable, with three named programs: 4ET1103 (lead neuropathic pain compound, completed Phase 1 with a favorable safety profile and demonstrated target engagement in human dorsal root ganglion neurons), 4ET2124 (clinical candidate for migraine, IND-enabling stage, with 4ET2104 as backup), and an earlier-stage acute pain program.

The company was led by CEO T. Craig Benson (since February 2020), co-founders Ted Price (Ashbel Smith Professor and Director of the Center for Advanced Pain Studies at UT Dallas) and Joe Price (President and Chairman), with a small executive team including a CMO with deep clinical pain research credentials. 4E operated as a lean, virtually-structured biotechnology company funded primarily through a $5.5 million NIH Phase 2 SBIR grant awarded in November 2021 under the NIH HEAL Initiative, plus prior NIH funding and undisclosed private capital (total disclosed funding approximately $10 million). The company had 11–50 employees and no commercial revenue; its business model was asset-based pharmaceutical R&D dependent on future licensing, partnership, or acquisition monetization. In June 2026, Eli Lilly acquired 4E Therapeutics for an undisclosed sum, absorbing its pipeline into Lilly's non-opioid pain portfolio as part of an aggressive early-stage neuroscience M&A push.

Short descriptiontext

4E Therapeutics is an Austin, Texas-based neuroscience drug developer (founded 2019) creating peripherally-restricted, orally-bioavailable small molecule MNK inhibitors for chronic neuropathic pain, migraine, and acute pain, acquired by Eli Lilly in June 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuropathic pain therapeutics, MNK inhibitor development, non-opioid pain medications, small molecule drug discovery, clinical stage biotechnology
Industry5 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
SECONDARYHLAKAIAE
Headache & Migraine Medicine
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pain Management Pharmaceuticals
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

4E Therapeutics is a neuroscience company developing a pipeline of peripherally-restricted, orally-bioavailable small molecule MNK inhibitors that target the MNK-eIF4E signaling pathway for the treatment of neuropathic pain, migraine, and acute pain. The portfolio includes lead compound 4ET1103 (Phase 1 completed for neuropathic pain), clinical candidate 4ET2124 (migraine), backup 4ET2104 (migraine), and a discovery-stage acute pain program. The compounds are designed to avoid central nervous system side effects common in existing pain therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 4ET1103 blocked evoked MNK activity in human dorsal root ganglion neurons from organ donors, demonstrating translational potential
+1 more record
Product overview1 text field

4E Therapeutics is a neuroscience company developing a pipeline of non-opioid therapeutic assets targeting the MNK-eIF4E signaling pathway for pain treatment. The company's portfolio includes three clinical-stage programs: 4ET1103 (lead compound for neuropathic pain, completed Phase 1), 4ET2124 (clinical candidate for migraine), and 4ET2104 (backup for migraine), along with a discovery-stage acute pain program. All candidates are peripherally-restricted, orally-bioavailable small molecule MNK inhibitors designed to avoid CNS side effects common in existing therapeutics.

Product and service4 records
14ET1103
CategoryDrug Candidate
Description

Lead compound for neuropathic pain; peripherally-restricted, orally-bioavailable small molecule MNK inhibitor that demonstrated favorable safety profile in Phase 1 studies and blocked evoked MNK activity in human dorsal root ganglion neurons. IND-enabling studies completed.

24ET2124
CategoryDrug Candidate
Description

Clinical candidate selected for migraine pain treatment; small molecule MNK inhibitor with excellent in vitro safety profile and efficacy across multiple animal models of migraine.

34ET2104
CategoryDrug Candidate
Description

Backup compound for migraine; small molecule MNK inhibitor positioned as backup to 4ET2124, with excellent in vitro safety profile and efficacy across multiple animal models of migraine.

4MNK-eIF4E Inhibitor Program (Acute Pain)
CategoryDrug Platform
Description

Peripherally-restricted small molecule MNK inhibitors targeting the MNK-eIF4E signaling pathway for acute pain treatment; non-brain penetrant compounds designed to avoid central-nervous-system side effects. Discovery stage.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeOthersAnnounced on2026-06-16
Description

Eli Lilly acquired 4E Therapeutics for an undisclosed sum as part of an aggressive M&A strategy targeting early-stage assets across neuroscience. The acquisition brings 4E's pipeline of oral MNK inhibitor medications for chronic pain under Lilly's clinical development and global commercial capabilities. This was Lilly's 11th acquisition announced in 2026.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major pharma with a chronic pain portfolio (including tanezumab, an anti-NGF therapy); competes broadly in the non-opioid pain therapeutics space with established commercial capabilities.

TypeBroad incumbent
Description

Through Allergan, AbbVie markets several pain therapeutics and is pursuing novel non-opioid pain assets, making it a broad incumbent competitor in chronic and neuropathic pain.

TypeDirect peer
Description

Vertex's NaV1.8 inhibitor suzetrigine (VX-548) is a leading non-opioid acute pain therapeutic approved by FDA, making Vertex the most directly comparable pain biotech pursuing novel-mechanism, non-opioid analgesia.

TypeBroad incumbent
Description

Major biotech with a pain portfolio including fasinumab (anti-NGF) and broad neuroscience capabilities; relevant broad incumbent competitor in non-opioid pain therapeutics.

TypeBroad incumbent
Description

Acquired CerSci Therapeutics (co-founded by 4E co-founder Ted Price) in 2020, positioning Acadia as a peer in the non-opioid neuropathic pain space and validating the same scientific founder's prior work.

TypeBroad incumbent
Description

Acquirer of 4E Therapeutics and a major pharma with a broad pain and neuroscience portfolio; comparable as the strategic acquirer validating and now developing 4E's MNK inhibitor assets.

TypeEmerging player
Description

Clinical-stage biotech developing non-opioid pain therapeutics targeting NaV1.8 and related ion channels; comparable as an emerging player pursuing novel mechanism pain drugs.

TypeEmerging player
Description

Clinical-stage biotech with non-opioid pain programs, including TNX-102 SL for fibromyalgia; comparable as an emerging player in non-opioid pain therapeutic development.

TypeDirect peer
Description

Specializes in migraine and neuroscience therapeutics (CGRP receptor antagonists such as rimegepant/Nurtec); directly relevant peer given 4E's migraine program 4ET2124.

TypeEmerging player
Description

Clinical-stage biotech developing NMDA receptor modulators for chronic pain and CNS disorders; comparable as an emerging player pursuing novel mechanism pain therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

4E Therapeutics

Pain Management Pharmaceuticals4etherapeutics.com

4E Therapeutics is an Austin, Texas-based neuroscience drug developer (founded 2019) creating peripherally-restricted, orally-bioavailable small molecule MNK inhibitors for chronic neuropathic pain, migraine, and acute pain, acquired by Eli Lilly in June 2026.

What 4E Therapeutics does

4E Therapeutics is a neuroscience drug development company founded in 2019 in Austin, Texas, focused on non-opioid treatments for chronic neuropathic pain and related pain disorders. The company's scientific premise is that MNK-mediated phosphorylation of eIF4E is the final common pathway linking injury to nociceptor plasticity that drives chronic pain, and that inhibiting this pathway in peripheral sensory neurons can suppress pain signal generation without the central nervous system side effects and addiction risk associated with opioid analgesics. Its core technology is a proprietary library of more than 150 small molecule MNK inhibitors, optimized through medicinal chemistry to be peripherally-restricted and orally bioavailable, with three named programs: 4ET1103 (lead neuropathic pain compound, completed Phase 1 with a favorable safety profile and demonstrated target engagement in human dorsal root ganglion neurons), 4ET2124 (clinical candidate for migraine, IND-enabling stage, with 4ET2104 as backup), and an earlier-stage acute pain program.

The company was led by CEO T. Craig Benson (since February 2020), co-founders Ted Price (Ashbel Smith Professor and Director of the Center for Advanced Pain Studies at UT Dallas) and Joe Price (President and Chairman), with a small executive team including a CMO with deep clinical pain research credentials. 4E operated as a lean, virtually-structured biotechnology company funded primarily through a $5.5 million NIH Phase 2 SBIR grant awarded in November 2021 under the NIH HEAL Initiative, plus prior NIH funding and undisclosed private capital (total disclosed funding approximately $10 million). The company had 11–50 employees and no commercial revenue; its business model was asset-based pharmaceutical R&D dependent on future licensing, partnership, or acquisition monetization. In June 2026, Eli Lilly acquired 4E Therapeutics for an undisclosed sum, absorbing its pipeline into Lilly's non-opioid pain portfolio as part of an aggressive early-stage neuroscience M&A push.

4E Therapeutics firmographics

Firmographics
Name
4E Therapeutics
Legal name
4E Therapeutics Inc
Website
https://4etherapeutics.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
1–10 employees
Short description
4E Therapeutics is an Austin, Texas-based neuroscience drug developer (founded 2019) creating peripherally-restricted, orally-bioavailable small molecule MNK inhibitors for chronic neuropathic pain, migraine, and acute pain, acquired by Eli Lilly in June 2026.
Ownership category
akta.pro rank

4E Therapeutics industry classification

Industry
Product category
Pain Management Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
SECONDARYHLAKAIAE
Headache & Migraine Medicine
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Neuropathic pain therapeutics
  • MNK inhibitor development
  • Non-opioid pain medications
  • Small molecule drug discovery
  • Clinical stage biotechnology

Where 4E Therapeutics is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

4E Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others

4E Therapeutics product offering

Product offering

Core offering

4E Therapeutics is a neuroscience company developing a pipeline of peripherally-restricted, orally-bioavailable small molecule MNK inhibitors that target the MNK-eIF4E signaling pathway for the treatment of neuropathic pain, migraine, and acute pain. The portfolio includes lead compound 4ET1103 (Phase 1 completed for neuropathic pain), clinical candidate 4ET2124 (migraine), backup 4ET2104 (migraine), and a discovery-stage acute pain program. The compounds are designed to avoid central nervous system side effects common in existing pain therapeutics.

Product overview

4E Therapeutics is a neuroscience company developing a pipeline of non-opioid therapeutic assets targeting the MNK-eIF4E signaling pathway for pain treatment. The company's portfolio includes three clinical-stage programs: 4ET1103 (lead compound for neuropathic pain, completed Phase 1), 4ET2124 (clinical candidate for migraine), and 4ET2104 (backup for migraine), along with a discovery-stage acute pain program. All candidates are peripherally-restricted, orally-bioavailable small molecule MNK inhibitors designed to avoid CNS side effects common in existing therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • 4ET1103 Lead compound for neuropathic pain; peripherally-restricted, orally-bioavailable small molecule MNK inhibitor that demonstrated favorable safety profile in Phase 1 studies and blocked evoked MNK activity in human dorsal root ganglion neurons. IND-enabling studies completed.
  • 4ET2124 Clinical candidate selected for migraine pain treatment; small molecule MNK inhibitor with excellent in vitro safety profile and efficacy across multiple animal models of migraine.
  • 4ET2104 Backup compound for migraine; small molecule MNK inhibitor positioned as backup to 4ET2124, with excellent in vitro safety profile and efficacy across multiple animal models of migraine.
  • MNK-eIF4E Inhibitor Program (Acute Pain) Peripherally-restricted small molecule MNK inhibitors targeting the MNK-eIF4E signaling pathway for acute pain treatment; non-brain penetrant compounds designed to avoid central-nervous-system side effects. Discovery stage.

Quantifiable outcome

  • 4ET1103 blocked evoked MNK activity in human dorsal root ganglion neurons from organ donors, demonstrating translational potential
  • +1 more outcomes

Companies that use 4E Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

4E Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

4E Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli Lilly and CompanyflagshipOthers · 16 June 2026Eli Lilly acquired 4E Therapeutics for an undisclosed sum as part of an aggressive M&A strategy targeting early-stage assets across neuroscience. The acquisition brings 4E's pipeline of oral MNK inhibitor medications for chronic pain under Lilly's clinical development and global commercial capabilities. This was Lilly's 11th acquisition announced in 2026.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

4E Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Major pharma with a chronic pain portfolio (including tanezumab, an anti-NGF therapy); competes broadly in the non-opioid pain therapeutics space with established commercial capabilities.
  • AbbVie: Through Allergan, AbbVie markets several pain therapeutics and is pursuing novel non-opioid pain assets, making it a broad incumbent competitor in chronic and neuropathic pain.
  • Regeneron Pharmaceuticals: Major biotech with a pain portfolio including fasinumab (anti-NGF) and broad neuroscience capabilities; relevant broad incumbent competitor in non-opioid pain therapeutics.
  • Acadia Pharmaceuticals: Acquired CerSci Therapeutics (co-founded by 4E co-founder Ted Price) in 2020, positioning Acadia as a peer in the non-opioid neuropathic pain space and validating the same scientific founder's prior work.
  • Eli Lilly and Company: Acquirer of 4E Therapeutics and a major pharma with a broad pain and neuroscience portfolio; comparable as the strategic acquirer validating and now developing 4E's MNK inhibitor assets.

Direct peers

  • Vertex Pharmaceuticals: Vertex's NaV1.8 inhibitor suzetrigine (VX-548) is a leading non-opioid acute pain therapeutic approved by FDA, making Vertex the most directly comparable pain biotech pursuing novel-mechanism, non-opioid analgesia.
  • Biohaven Pharmaceuticals: Specializes in migraine and neuroscience therapeutics (CGRP receptor antagonists such as rimegepant/Nurtec); directly relevant peer given 4E's migraine program 4ET2124.

Emerging players

  • Latigo Biotherapeutics: Clinical-stage biotech developing non-opioid pain therapeutics targeting NaV1.8 and related ion channels; comparable as an emerging player pursuing novel mechanism pain drugs.
  • Tonix Pharmaceuticals: Clinical-stage biotech with non-opioid pain programs, including TNX-102 SL for fibromyalgia; comparable as an emerging player in non-opioid pain therapeutic development.
  • Aptinyx: Clinical-stage biotech developing NMDA receptor modulators for chronic pain and CNS disorders; comparable as an emerging player pursuing novel mechanism pain therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

4E Therapeutics social profiles

Digital presence

4E Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

4E Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

4E Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

4E Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4E Therapeutics

What does 4E Therapeutics do?

4E Therapeutics is a neuroscience company developing a pipeline of peripherally-restricted, orally-bioavailable small molecule MNK inhibitors that target the MNK-eIF4E signaling pathway for the treatment of neuropathic pain, migraine, and acute pain. The portfolio includes lead compound 4ET1103 (Phase 1 completed for neuropathic pain), clinical candidate 4ET2124 (migraine), backup 4ET2104 (migraine), and a discovery-stage acute pain program. The compounds are designed to avoid central nervous system side effects common in existing pain therapeutics.

Is 4E Therapeutics a public or private company?

4E Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was 4E Therapeutics founded?

4E Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is 4E Therapeutics based?

4E Therapeutics is headquartered in Austin, United States, in the North America region.

Who are 4E Therapeutics's main competitors?

Broad incumbents on record are Pfizer, AbbVie, Regeneron Pharmaceuticals, Acadia Pharmaceuticals and Eli Lilly and Company. Direct peers are Vertex Pharmaceuticals and Biohaven Pharmaceuticals. Emerging players are Latigo Biotherapeutics, Tonix Pharmaceuticals and Aptinyx.

Does 4E Therapeutics have an API?

No public API is recorded for 4E Therapeutics.

What industry is 4E Therapeutics in?

4E Therapeutics's product category is Pain Management Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolSnap’s Specs GambleSnap introduced its Specs AR glasses at $2,195, but the high price and unproven form factor make them a tough sell. Snap's business is struggling with a net loss and only 5% daily active user growth. Rivian announced layoffs in customer service and marketing, and Eli Lilly acquired 4E Therapeutics for pain drugs.TheStreet.comCathie Wood dumps nearly $60 million in popular growth stocksCathie Wood's ARK Invest sold Robinhood and Roku shares after their rallies, taking about $60 million in profits. The firm then added positions in Eli Lilly, Coinbase, and Block, shifting toward companies with fresh catalysts. The rotation signals Wood's willingness to lock in gains when upside becomes defined.Seeking AlphaEli Lilly: Pharma With Unstoppable Momentum Targets Pain With Latest M&A Deal (NYSE:LLY)Eli Lilly has acquired pain management specialist 4E Therapeutics, for an undisclosed sum, as part of an aggressive M&A strategy to diversify beyond its dominant tirzepatide franchise, which generated approximately $36.5 billion in 2024 revenues and outsold Novo Nordisk's semaglutide products. The Indianapolis-based pharmaceutical company, now the world's most valuable pharma with a market cap exceeding $1 trillion, has completed multiple acquisitions in 2026 across neuroscience, oncology, immunology, and cardiometabolic health—including deals for Orna Therapeutics ($2.4bn), Kelonia ($7bn), Centessa Pharmaceuticals ($6.3bn), and a $8.85bn partnership with China's Innovent—leveraging over $16.8 billion in 2025 operating cash flow to target over $120 billion in revenues by 2030.The Pharma LetterEli Lilly buys 4E to deepen non-opioid pain pushEli Lilly acquired 4E Therapeutics, adding a pipeline of oral MNK inhibitors for chronic pain without CNS effects. The deal's financial terms were not disclosed. The lead candidate, 4ET1103, targets the MNK-eIF4E signaling pathway in peripheral sensory neurons.MarketScreenerHealthcare Stocks Decline Amid Broad Selloff -- Healthcare RoundupHealthcare stocks declined as markets reacted to elevated U.S. borrowing costs. 4E Therapeutics was acquired by Eli Lilly, and Leerink Partners raised its UnitedHealth price target to $462 from $400, citing higher margin forecasts for Optum Health.WsjHealth Care Roundup: Market TalkEli Lilly has acquired 4E Therapeutics, an Austin-based neuroscience company developing treatments for chronic pain with compounds designed to provide pain relief while avoiding central nervous system side effects common in existing therapeutics. The companies did not disclose the terms of the deal. The acquisition brings 4E's chronic pain research pipeline under Lilly's clinical development and global commercial capabilities.Pulse 2.0Lilly Acquires 4E Therapeutics To Advance Non-Opioid Chronic Pain TreatmentsEli Lilly and Company has acquired Austin-based neuroscience company 4E Therapeutics, which is developing a pipeline of orally available MNK inhibitors for chronic pain treatment through a non-opioid approach. 4E's lead candidate 4ET1103 became the first MNK inhibitor developed for pain to enter human clinical trials and demonstrated a favorable safety profile in a Phase 1 study. The acquisition brings 4E's science into Lilly's pipeline, with the potential to accelerate new therapies to patients living with chronic pain.PR Newswire4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic PainEli Lilly and Company has acquired 4E Therapeutics, an Austin-based neuroscience company developing non-opioid treatments for chronic pain using MNK inhibitors that target the MNK-eIF4E signaling pathway in peripheral sensory neurons. 4E's lead compound 4ET1103 is the first MNK inhibitor for pain to advance to human clinical trials, demonstrating a favorable safety profile in Phase 1 studies. Terms of the transaction were not disclosed.MorningstarHealth Care Flat as Traders Rotate Into Laggards From Tech - Health Care RoundupHealth-care stocks were flat as traders rotated into laggards from the volatile technology sector. Eli Lilly agreed to buy neuroscience firm 4E Therapeutics, and Amphastar Pharmaceuticals received FDA approval for an over-the-counter nasal spray to treat opioid overdose.MarketScreenerHealth Care Flat as Traders Rotate Into Laggards From Tech - Health Care RoundupHealth-care stocks were flat as traders rotated into laggards from the volatile technology sector. Eli Lilly agreed to buy neuroscience firm 4E Therapeutics, and Amphastar Pharmaceuticals received FDA approval for an over-the-counter nasal spray to treat opioid overdose.